FR-Nice-CAL
Welcome,         Profile    Billing    Logout  
 8 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gastaud, Lauris
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
EREMISS, NCT03793361: Phase II Study of Regorafenib as Maintenance Therapy

Completed
2
127
Europe
Regorafenib, stivarga, Placebo
Centre Oscar Lambret
Metastatic Soft Tissue Sarcoma
03/24
09/24
DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Hourglass Jul 2024 - Dec 2024 : Data for RRMM
Active, not recruiting
2
177
Europe, Canada, US, RoW
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
08/24
01/26
CPX-351 TA-SMP, NCT04992949: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Completed
2
42
Europe
CPX-351
French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes
Acute Myeloid Leukemia, Myeloproliferative Syndrome
10/23
12/23
AGORA-1, NCT05199051 / 2021-001813-35: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML

Recruiting
2
50
Europe
Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata
Centre Antoine Lacassagne, Acute Leukemia French Association, Astellas Pharma Inc, Pfizer
AML
03/27
03/27
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting
2
210
Europe
Cytarabine and Idarubicin, CPX-315
Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association
Acute Myeloid Leukemia
10/27
10/27
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
02/27
02/27
NCT01210274: Characterization of the Mechanisms of Resistance to Azacitidine

Recruiting
N/A
250
Europe, RoW
Centre Hospitalier Universitaire de Nice
Myelodysplastic Syndromes or Acute Myeloid Leukemia with Multilineage Dysplasia
09/14
09/25
LYMPHODTECT, NCT03121456: 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma

Active, not recruiting
N/A
74
Europe
18F-FDG PET SCAN, MRI DIFFUSION
Centre Antoine Lacassagne
Diffuse Large B Cell Lymphoma
04/24
04/24
EarlyTogether, NCT04728113: Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients

Completed
N/A
162
Europe
Supportive care visit with questionnaires, Oncological standard visit
Institut Curie
Uveal Melanoma
01/25
01/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gastaud, Lauris
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
EREMISS, NCT03793361: Phase II Study of Regorafenib as Maintenance Therapy

Completed
2
127
Europe
Regorafenib, stivarga, Placebo
Centre Oscar Lambret
Metastatic Soft Tissue Sarcoma
03/24
09/24
DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Hourglass Jul 2024 - Dec 2024 : Data for RRMM
Active, not recruiting
2
177
Europe, Canada, US, RoW
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
08/24
01/26
CPX-351 TA-SMP, NCT04992949: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Completed
2
42
Europe
CPX-351
French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes
Acute Myeloid Leukemia, Myeloproliferative Syndrome
10/23
12/23
AGORA-1, NCT05199051 / 2021-001813-35: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML

Recruiting
2
50
Europe
Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata
Centre Antoine Lacassagne, Acute Leukemia French Association, Astellas Pharma Inc, Pfizer
AML
03/27
03/27
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting
2
210
Europe
Cytarabine and Idarubicin, CPX-315
Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association
Acute Myeloid Leukemia
10/27
10/27
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
02/27
02/27
NCT01210274: Characterization of the Mechanisms of Resistance to Azacitidine

Recruiting
N/A
250
Europe, RoW
Centre Hospitalier Universitaire de Nice
Myelodysplastic Syndromes or Acute Myeloid Leukemia with Multilineage Dysplasia
09/14
09/25
LYMPHODTECT, NCT03121456: 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma

Active, not recruiting
N/A
74
Europe
18F-FDG PET SCAN, MRI DIFFUSION
Centre Antoine Lacassagne
Diffuse Large B Cell Lymphoma
04/24
04/24
EarlyTogether, NCT04728113: Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients

Completed
N/A
162
Europe
Supportive care visit with questionnaires, Oncological standard visit
Institut Curie
Uveal Melanoma
01/25
01/25

Download Options